JP2013544860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544860A5 JP2013544860A5 JP2013542482A JP2013542482A JP2013544860A5 JP 2013544860 A5 JP2013544860 A5 JP 2013544860A5 JP 2013542482 A JP2013542482 A JP 2013542482A JP 2013542482 A JP2013542482 A JP 2013542482A JP 2013544860 A5 JP2013544860 A5 JP 2013544860A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- phenyl
- haloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- -1 pyrimidinyl compound Chemical class 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010079465 | 2010-12-06 | ||
| CNPCT/CN2010/079465 | 2010-12-06 | ||
| PCT/EP2011/071690 WO2012076435A1 (en) | 2010-12-06 | 2011-12-05 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544860A JP2013544860A (ja) | 2013-12-19 |
| JP2013544860A5 true JP2013544860A5 (enExample) | 2015-01-29 |
| JP5886310B2 JP5886310B2 (ja) | 2016-03-16 |
Family
ID=45440490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542482A Expired - Fee Related JP5886310B2 (ja) | 2010-12-06 | 2011-12-05 | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US8637536B2 (enExample) |
| EP (1) | EP2649053B1 (enExample) |
| JP (1) | JP5886310B2 (enExample) |
| KR (1) | KR101861883B1 (enExample) |
| CN (2) | CN104478812A (enExample) |
| AR (1) | AR084153A1 (enExample) |
| AU (1) | AU2011340690C1 (enExample) |
| BR (1) | BR112013013898B1 (enExample) |
| CA (1) | CA2820408C (enExample) |
| CL (1) | CL2013001604A1 (enExample) |
| CO (1) | CO6801726A2 (enExample) |
| CR (1) | CR20130264A (enExample) |
| DO (1) | DOP2013000130A (enExample) |
| EA (1) | EA023796B1 (enExample) |
| ES (1) | ES2559224T3 (enExample) |
| IL (1) | IL226473A0 (enExample) |
| MX (1) | MX2013006342A (enExample) |
| PE (1) | PE20140421A1 (enExample) |
| PH (1) | PH12013501089A1 (enExample) |
| SG (1) | SG190830A1 (enExample) |
| TW (1) | TW201307324A (enExample) |
| UY (1) | UY33766A (enExample) |
| WO (1) | WO2012076435A1 (enExample) |
| ZA (1) | ZA201303560B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349577B2 (en) * | 2009-04-23 | 2013-01-08 | Research Foundation For Mental Hygiene, Inc. | Method for evaluating blood-neural barrier permeability |
| WO2012075917A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Compounds |
| US8637536B2 (en) * | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| US9227953B2 (en) | 2011-09-01 | 2016-01-05 | Glaxo Group Limited | Crystal form |
| JP6037277B2 (ja) * | 2012-12-19 | 2016-12-07 | 国立研究開発法人農業・食品産業技術総合研究機構 | オーキシン生合成阻害剤 |
| CA2899124A1 (en) * | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| WO2015027067A2 (en) * | 2013-08-23 | 2015-02-26 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN103896906A (zh) * | 2014-02-28 | 2014-07-02 | 苏州维泰生物技术有限公司 | 一种农药咯菌腈中间体的新合成方法 |
| WO2016002918A1 (ja) * | 2014-07-04 | 2016-01-07 | 日本たばこ産業株式会社 | インドール化合物の製造方法 |
| WO2016012916A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| WO2016012917A1 (en) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2 |
| CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
| CN110283803B (zh) * | 2016-06-02 | 2021-08-03 | 天津科技大学 | 一种磷脂酶d及其制备磷脂酸、磷脂酰丝氨酸的方法 |
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| FI4081511T6 (fi) * | 2019-12-23 | 2026-06-09 | Sitryx Therapeutics Ltd | Karboksijohdannaisia, joilla on anti-inflammatorisia ominaisuuksia |
| CN113666930B (zh) * | 2020-05-13 | 2022-10-25 | 上海纽思克生物科技有限公司 | 桥环嘧啶酮类化合物、其制备方法、其组合物和用途 |
| CN111533699B (zh) * | 2020-05-27 | 2023-12-01 | 龙曦宁（上海）医药科技有限公司 | 一种2-（三氟甲基）嘧啶-5-醇的合成方法 |
| US20250063616A1 (en) * | 2022-02-03 | 2025-02-20 | Qualcomm Incorporated | Energy harvesting for component carrier and bandwidth part pairings |
| JP2025527291A (ja) * | 2022-08-04 | 2025-08-20 | ４ビー テクノロジーズ （ベイジン） カンパニー リミテッド | Ｌｐ－ＰＬＡ２阻害剤としてのジヒドロイミダゾピリミジノン化合物およびその使用 |
| CN118221687B (zh) | 2023-07-17 | 2024-12-31 | 上海枢境生物科技有限公司 | 双环[5,6]咪唑嘧啶酮类衍生物、其制备方法和应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| WO1996019451A1 (en) | 1994-12-22 | 1996-06-27 | Smithkline Beecham Plc | Substituted azetidin-2-ones for treatment of atherosclerosis |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| HUP9901153A3 (en) | 1995-07-01 | 1999-11-29 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them |
| WO1997012963A2 (en) | 1995-09-29 | 1997-04-10 | Smithkline Beecham Plc | A paf-acetylhydrolase and use in therapy |
| EP0869943A1 (en) | 1995-12-08 | 1998-10-14 | Smithkline Beecham Plc | Monocyclic beta-lactame derivatives for treatment of atherosclerosis |
| EP0865429A1 (en) | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
| CZ341098A3 (cs) | 1996-04-26 | 1999-03-17 | Smithkline Beecham Plc | Azetidinonové deriváty pro ošetřování aterosklerózy |
| GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| ATE289295T1 (de) | 1997-04-22 | 2005-03-15 | Euro Celtique Sa | Die verwendung von durch carbozyklische und heterozyklische reste substituierte semicarbazonen und thiosemicarbazonen als natriumkanalblocker |
| WO1999024420A1 (en) | 1997-11-06 | 1999-05-20 | Smithkline Beecham Plc | Pyrimidinone compounds and pharmaceutical compositions containing them |
| DE69911980T2 (de) | 1998-08-21 | 2004-09-09 | Smithkline Beecham P.L.C., Brentford | Pyrimidinonderivate zur behandlung von atheroscleros |
| GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| DE60042286D1 (de) | 1999-05-01 | 2009-07-09 | Smithkline Beecham Plc | Pyrimidinon Verbindungen |
| GB9910378D0 (en) * | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
| JP3757703B2 (ja) | 1999-09-22 | 2006-03-22 | 凸版印刷株式会社 | 再封可能な開口維持部材付パウチ |
| DE60139429D1 (de) * | 2000-02-16 | 2009-09-10 | Smithkline Beecham Plc | Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren |
| GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| SI1762567T1 (sl) * | 2001-04-10 | 2012-08-31 | Pfizer | Derivati pirazola za zdravljenje HIV-a |
| GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
| GB0119793D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
| GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127143D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0127140D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
| GB0208280D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| EP1644353A1 (de) | 2003-07-02 | 2006-04-12 | Bayer HealthCare AG | Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten |
| DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
| DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
| US20080090851A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| WO2008048867A2 (en) | 2006-10-13 | 2008-04-24 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US20080090852A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
| US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
| US9029383B2 (en) | 2007-05-11 | 2015-05-12 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| WO2012075917A1 (en) * | 2010-12-06 | 2012-06-14 | Glaxo Group Limited | Compounds |
| US8637536B2 (en) * | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
-
2011
- 2011-12-05 US US13/310,818 patent/US8637536B2/en not_active Expired - Fee Related
- 2011-12-05 EA EA201390826A patent/EA023796B1/ru not_active IP Right Cessation
- 2011-12-05 MX MX2013006342A patent/MX2013006342A/es unknown
- 2011-12-05 UY UY0001033766A patent/UY33766A/es unknown
- 2011-12-05 AU AU2011340690A patent/AU2011340690C1/en not_active Ceased
- 2011-12-05 CA CA2820408A patent/CA2820408C/en active Active
- 2011-12-05 AR ARP110104535A patent/AR084153A1/es unknown
- 2011-12-05 ES ES11802872.9T patent/ES2559224T3/es active Active
- 2011-12-05 WO PCT/EP2011/071690 patent/WO2012076435A1/en not_active Ceased
- 2011-12-05 PH PH1/2013/501089A patent/PH12013501089A1/en unknown
- 2011-12-05 CN CN201410575164.7A patent/CN104478812A/zh active Pending
- 2011-12-05 SG SG2013038427A patent/SG190830A1/en unknown
- 2011-12-05 CN CN201180066903.4A patent/CN103347864B/zh not_active Expired - Fee Related
- 2011-12-05 EP EP11802872.9A patent/EP2649053B1/en active Active
- 2011-12-05 PE PE2013001234A patent/PE20140421A1/es not_active Application Discontinuation
- 2011-12-05 TW TW100144556A patent/TW201307324A/zh unknown
- 2011-12-05 JP JP2013542482A patent/JP5886310B2/ja not_active Expired - Fee Related
- 2011-12-05 KR KR1020137017621A patent/KR101861883B1/ko not_active Expired - Fee Related
- 2011-12-05 BR BR112013013898-0A patent/BR112013013898B1/pt not_active IP Right Cessation
- 2011-12-05 US US13/991,955 patent/US20130252963A1/en not_active Abandoned
-
2012
- 2012-10-17 DO DO2013000130A patent/DOP2013000130A/es unknown
-
2013
- 2013-05-16 ZA ZA2013/03560A patent/ZA201303560B/en unknown
- 2013-05-20 IL IL226473A patent/IL226473A0/en unknown
- 2013-06-05 CL CL2013001604A patent/CL2013001604A1/es unknown
- 2013-06-07 CO CO13138754A patent/CO6801726A2/es active IP Right Grant
- 2013-09-06 CR CR20130264A patent/CR20130264A/es unknown
- 2013-12-19 US US14/133,720 patent/US20140113922A1/en not_active Abandoned
-
2014
- 2014-12-15 US US14/569,970 patent/US9174968B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537203A5 (enExample) | ||
| JP2014520898A5 (enExample) | ||
| JP2013540755A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2016506960A5 (enExample) | ||
| JP2014521625A5 (enExample) | ||
| JP2014507464A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| JP2011519854A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2010540525A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2015520140A5 (enExample) | ||
| JP2013502441A5 (enExample) | ||
| JP2013542218A5 (enExample) | ||
| JP2013508288A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2010031025A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| JP2013505969A5 (enExample) |